Luminex Corporation issued the following announcement on July 1.
Luminex Corporation (NASDAQ: LMNX) announced that the company submitted the ARIES® MRSA Assay to the U.S. Food and Drug Administration (FDA) for clearance on Friday, June 28, 2019. The assay is a real-time, quantitative polymerase chain reaction (qPCR)-based, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.
"This submission demonstrates our continued dedication to expanding the menu of clinically relevant and high-value tests that support patient care throughout the world on our sample to answer platforms," said Homi Shamir, President and CEO of Luminex. "Our VERIGENE® II GI Flex and RSP Flex submissions, as well as the commercialization of our new SENSIPLEX™ instrument, remain on track with our previously communicated timelines."
According to the U.S. Centers for Disease Control and Prevention, in 2016, there was approximately one case of MRSA for every 30 people in the U.S. This works out to around 10 million cases of MRSA in the U.S. each year.1,2 Rapid molecular tests for organisms such as MRSA have the potential to aid physicians in reigning in the spread of antimicrobial resistance and the associated negative outcomes for both patients and healthcare facilities by reducing the unnecessary use of antimicrobial therapies, thus allowing for more effective patient management.
The Luminex ARIES® System is a sample to answer, real-time system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory. The system already offers six FDA and seven CE-IVD cleared assays, as well as the ability to run laboratory developed tests. "This assay will add another foundational test to the ARIES® System, increasing its value for customers and patients," said Shamir.
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at www.luminexcorp.com.
Original source can be found here.
